Last reviewed · How we verify
intensive insulin group
intensive insulin group is a Small molecule drug developed by Kyunghee University Medical Center. It is currently FDA-approved. Also known as: Lantus Insulin, Apidra Insulin.
At a glance
| Generic name | intensive insulin group |
|---|---|
| Also known as | Lantus Insulin, Apidra Insulin |
| Sponsor | Kyunghee University Medical Center |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Role of Combination Therapy of Glucose Insulin Potassium Infusion (GIK), Intravenous Hydrocortisone and Oral Sevelamer in Treatment of Acute Aluminum Phosphide Poisoned Cases Admitted to Intensive Care Unit (ICU) at Sohag University Hospitals. (NA)
- A 12-week Pilot Nutrition Intervention for Children With New Diagnosis of Stage 3 Type 1 Diabetes (T1D) (NA)
- Relapse Among Diabetic Ketoacidosis Patients Maintained Basal Bolus Insulin Administration in Combination With Continuous Intravenous Insulin Infusion VS Non Maintaining Basal Insulin Patients (NA)
- Regimen Transition After Short-Term Intensive Insulin Therapy in Type 2 Diabetes (PHASE4)
- Effect of Low-intensity Aerobic Regular Activity on Heart Rate Variability in Type 1 Diabetes (NA)
- To Evaluate the Change in Glucose Parameters in Adult Patients With Type 1 or Type 2 Diabetes From Europe Using the iCan o3 CGM System for 60 Days Period (NA)
- Effect of Conventional vs Intensive Management on Gestational Diabetes and Maternal Fetal Outcomes (NA)
- Effect of Intensive Nutrition Training, Education, and Support in Gestational Diabetes - The INTENSE-GDM TRIAL (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- intensive insulin group CI brief — competitive landscape report
- intensive insulin group updates RSS · CI watch RSS
- Kyunghee University Medical Center portfolio CI
Frequently asked questions about intensive insulin group
What is intensive insulin group?
intensive insulin group is a Small molecule drug developed by Kyunghee University Medical Center.
Who makes intensive insulin group?
intensive insulin group is developed and marketed by Kyunghee University Medical Center (see full Kyunghee University Medical Center pipeline at /company/kyunghee-university-medical-center).
Is intensive insulin group also known as anything else?
intensive insulin group is also known as Lantus Insulin, Apidra Insulin.
What development phase is intensive insulin group in?
intensive insulin group is FDA-approved (marketed).
Related
- Manufacturer: Kyunghee University Medical Center — full pipeline
- Also known as: Lantus Insulin, Apidra Insulin
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing